CEVA, Inc. CEVA 深 沪
等待开盘 04-01 09:30:00 美东时间
18.68
+1.470
+8.54%
华盛通- 最 高18.70
- 今 开17.54
- 成交量 34.56万股
- 最 低 17.40
- 昨 收 17.21
- 总市值 5.18亿
- 52周最高 30.88
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 17.02
- 委 比 -90.90%
- 总股本 2775.41万
- 历史最高 83.95
- 量 比 1.16
- 振 幅 7.55%
- 历史最低 12.56
- 每 手 1
- 风险率 2.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
TD Cowen Initiates Coverage On CEVA with Buy Rating, Announces Price Target of $22
TD Cowen analyst Joshua Buchalter initiates coverage on CEVA (NASDAQ:CEVA) with a Buy rating and announces Price Target of $22.
03-20 23:44
This US Bancorp Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
02-27 02:37
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
UBS Initiates Coverage On CEVA with Buy Rating, Announces Price Target of $27
UBS analyst Natalia Winkler initiates coverage on CEVA (NASDAQ:CEVA) with a Buy rating and announces Price Target of $27.
02-25 20:51
Ceva Stock Remains Constrained As Momentum Fails To Build
An analysis of Ceva Stock's outlook, explaining why it may remain constrained as momentum struggles to build.
02-19 21:41
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
Rosenblatt Maintains Buy on CEVA, Maintains $40 Price Target
Rosenblatt analyst Kevin Cassidy maintains CEVA (NASDAQ:CEVA) with a Buy and maintains $40 price target.
02-18 20:33
Ceva shares are trading lower. The company announced Q4 financial results.
Ceva shares are trading lower. The company announced Q4 financial results.
02-18 01:50
CEVA: Q4 Earnings Insights
The earnings results for CEVA (NASDAQ:CEVA) for Q4 were made public on Tuesday,...
02-17 20:04
